Though sellar pituitary cytomas belong to a rare category of intracranial tumors, their anatomical location within a critical skull base region frequently triggers endocrine disorders and compressive neurological symptoms, severely impairing patients’ quality of life. Advances in medical technology such as endoscopic surgery and targeted therapy have reshaped the therapeutic landscape of this disease. Drawing on the latest 2025 clinical research progress, this article delivers an in-depth systematic analysis covering pathological mechanisms, early symptom identification, standardized diagnostic workflows and cutting-edge therapeutic technologies to provide a full overview of diagnosis and management for sellar pituitary cytomas.

I. Pathological Characteristics and Epidemiological Trends

Sellar pituitary cytomas originate from adenohypophyseal cells, accounting for 1%–2% of all intracranial neoplasms with an annual incidence of 0.1–0.2 per 100,000 people. The predominant pathological subtypes include prolactin-secreting adenomas (PRL), growth hormone-secreting adenomas (GH) and adrenocorticotropic hormone-secreting adenomas (ACTH), followed by non-functional adenomas. Notably, functional adenomas mostly develop in patients aged 30 to 50 years, while non-functional adenomas are more prevalent among middle-aged and elderly populations.

Core Pathological Features

Aberrant hormone secretion

PRL adenomas cause amenorrhea-galactorrhea syndrome in females and erectile dysfunction in males; GH adenomas induce acromegaly; ACTH adenomas present with full-spectrum Cushing syndrome manifestations.

Invasive biological behavior

Approximately 35% of pituitary cytomas display invasive growth, capable of infiltrating the cavernous sinus, sphenoid sinus and other adjacent bony and neurovascular structures, significantly raising surgical technical difficulty.

Elevated recurrence risk

Atypical pituitary cytomas (mitotic count > 2 per 10 high-power fields, Ki-67 index > 3%) carry a 40% 5-year postoperative recurrence rate.

II. Symptom Recognition and Early Diagnosis

1. Neurological Compressive Manifestations

Visual impairment: Around 60% of patients develop bitemporal hemianopia secondary to optic chiasm compression, with complete blindness occurring in severe cases.

Headache: Two-thirds of patients complain of dull bifrontal or temporal cephalalgia; pituitary apoplexy triggers sudden explosive headache accompanied by altered consciousness.

Cavernous sinus syndrome: Tumor infiltration into the cavernous sinus leads to diplopia, ptosis (oculomotor nerve palsy) and facial hypoesthesia (trigeminal nerve involvement).

2. Endocrine Disturbances by Tumor Subtype

3. Standard Diagnostic Workflow

Laboratory Endocrine Testing

Baseline hormonal panel: PRL, GH, IGF-1, ACTH, serum cortisol and other core pituitary hormones.

Dynamic functional stimulation/suppression tests: Oral glucose GH suppression test (for GH adenomas); low- and high-dose dexamethasone suppression test (for ACTH adenomas).

Radiological Evaluation

Sellar MRI: Contrast-enhanced T1-weighted sequences clearly delineate tumor borders and invasive extension range; T2-weighted imaging reflects intratumoral cellular density.

CT angiography (CTA): Three-dimensional reconstruction visualizes anatomical relationships between the tumor, internal carotid artery and cavernous sinus to guide surgical corridor planning.

Histopathological Biopsy

Tissue specimens are harvested transsphenoidally during surgery, with immunohistochemical staining performed to detect hormone markers including synaptophysin and chromogranin A. A Ki-67 proliferation index exceeding 3% indicates elevated malignant potential of the lesion.

III. Therapeutic Strategies and Technical Breakthroughs

1. Surgical Resection

Endoscopic Endonasal Transsphenoidal Surgery

Technical advantages: The natural nasal anatomical corridor provides direct access to sellar lesions without craniotomy-related trauma. Intraoperative 5-ALA fluorescence navigation achieves real-time differentiation between neoplastic tissue and intact normal parenchyma, lifting gross total resection rates to 85%.

Clinical case illustration: The Wu Zhebao team at Ruijin Hospital completed transsphenoidal resection of a GH adenoma in an 80-year-old elderly patient in 2025. Postoperative IGF-1 dropped from 341 ng/mL to 291 ng/mL with zero perioperative complications recorded.

Craniotomy

Indications: Tumors with extensive suprasellar and parasellar cavernous sinus invasion, or recurrent lesions unsuitable for endoscopic resection.

Technical reference: Xuanwu Hospital implements internal carotid artery-middle cerebral artery bypass grafting to enable radical tumor excision while preserving neurological function in patients with recurrent malignant meningeal tumors.

2. Radiation Therapy

Stereotactic Radiosurgery (SRS)

Gamma Knife single-fraction irradiation with marginal doses of 12–20 Gy delivers long-term growth control for non-functional adenomas, achieving an 85% 5-year local control rate. AI-assisted target segmentation models (nnU-Net) improve delineation precision and lower incidental optic nerve radiation injury risk.

Fractionated Stereotactic Radiotherapy

Indicated for large-volume tumors or postoperative residual disease; total prescription dose 45–50 Gy delivered over 25–30 treatment fractions.

3. Medical Pharmacotherapy

Dopamine receptor agonists

Bromocriptine and cabergoline achieve a treatment response rate over 80% for prolactinomas, inducing more than 50% reduction in tumor volume for most lesions.

Somatostatin analogues

Octreotide and lanreotide suppress excess GH secretion to alleviate acromegalic symptoms; combined adjuvant radiotherapy further elevates therapeutic efficacy.

Targeted molecular agents

BRAF inhibitors: Dabrafenib yields a 40% objective response rate for tumors harboring BRAF V600E mutations (recommended per 2024 NCCN clinical practice guidelines).

mTOR inhibitor everolimus: Prescribed for invasive refractory pituitary cytomas, extending median progression-free survival to 10.8 months.

4. Multimodal Combined Therapy

Preoperative tumor embolization: For highly vascularized lesions, preoperative embolization of feeding arteries drastically reduces intraoperative hemorrhage (e.g., blood loss reduced from 2000 mL to 400 mL in meningeal tumor cases).

Postoperative adjuvant therapy: Adjuvant radiotherapy following resection of atypical pituitary cytomas cuts the 5-year recurrence rate from 40% down to 15%.

IV. Postoperative Management and Long-Term Surveillance

1. Prevention and Control of Surgical Complications

Cerebrospinal fluid (CSF) rhinorrhea: Baseline incidence 3%–12%; nasoseptal mucosal flap reconstruction reduces this risk to 3%.

Diabetes insipidus: Incidence approximately 18%, requiring serial serum sodium monitoring and desmopressin (DDAVP) supplementation.

Permanent hypopituitarism: Lifelong hormone replacement therapy including hydrocortisone, levothyroxine and sex hormone preparations.

2. Rehabilitation Training and Psychological Support

Early rehabilitation (Weeks 1–2): Swallowing training combining cold ice stimulation and lingual muscle exercise.

Intermediate rehabilitation (Weeks 3–4): Balance training using Bobath therapy balls.

Late functional recovery (Months 1–3): Occupational rehabilitation including typing practice and driving simulation training.

Mental health intervention: Approximately 30% of patients develop postoperative anxiety and depression, requiring cognitive behavioral therapy (CBT).

3. Standardized Follow-Up Regimen

Radiological surveillance: Contrast-enhanced sellar MRI at 3 months, 6 months and 1 year postoperatively, followed by annual scans indefinitely.

Endocrine testing: Serial serum PRL, GH, ACTH and related hormone assays every 3–6 months.

Recurrence risk stratification: Ki-67 index testing every 6 months for patients with invasive tumors.

V. Cutting-Edge Research and Future Therapeutic Directions

Artificial intelligence assisted precision treatment

Deep learning segmentation models (nnU-Net) automatically outline tumor boundaries, shortening stereotactic radiosurgery planning time by 30%.

Immune checkpoint immunotherapy

Combination therapy of pembrolizumab (PD-1 inhibitor) and radiotherapy achieves a 30% objective response rate for refractory pituitary cytomas.

CRISPR gene editing technology

CRISPR-Cas9 mediated targeted knockout of TERT mutant genes inhibits tumor progression; preclinical animal trials demonstrated a 99.9% reduction in tumor volume.

VI. Typical Clinical Case Analysis

Case 1: Minimally Invasive Endoscopic Resection for Elderly Patients

A 72-year-old female patient presented with persistent headache; MRI confirmed an intrasellar craniopharyngioma. Complete gross total resection was performed via endoscopic endonasal transsphenoidal corridor with intraoperative sellar floor reconstruction to prevent CSF leak. The patient was discharged after 10 days of uncomplicated recovery.

Case 2: Multimodal Comprehensive Therapy for Recurrent Tumors

A 42-year-old male patient suffered two successive tumor recurrences after primary surgery. A combined regimen of endoscopic resection, intraoperative magnetic navigation and postoperative proton beam radiotherapy was implemented, yielding 5 years of progression-free survival with visual acuity recovered to 0.6.

VII. Clinical Decision-Making Guide for Treatment Selection

1. Comparison of Surgical Modalities

2. Criteria for Selecting Hospitals and Surgeons

Prioritize neurosurgical centers performing more than 100 pituitary tumor operations annually.

Attending surgeons must possess multidisciplinary collaborative capabilities with integrated endocrinology and radiation oncology teams.

Confirm the hospital is equipped with high-end intraoperative imaging systems including intraoperative MRI and stereotactic neuro-navigation.

Conclusion

The diagnosis and treatment of sellar pituitary cytomas have entered an era of precision, minimally invasive and individualized care. Multimodal radiological assessment, iterative endoscopic surgical innovation, targeted pharmaceutical development and AI-assisted treatment planning have drastically improved patient survival rates and long-term quality of life. Looking ahead, breakthroughs in gene editing and immunotherapy will further optimize the efficacy of combined surgical, radiotherapeutic and targeted regimens, delivering expanded therapeutic hope for affected patients.